PQR530

PQR530 is a potent, orally bioavailable, and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor developed as a follow-up compound to bimiralisib (PQR309). It targets all class IA phosphoinositide 3-kinase (PI3K) isoforms as well as both mTOR complexes (mTORC1 and mTORC2). The PI3K/AKT/mTOR signaling pathway is a critical regulator of cell proliferation, growth, and survival, and its aberrant activation is a common driver in various malignancies. PQR530 has demonstrated significant anti-tumor activity in preclinical models, including melanoma cell lines, and its ability to cross the blood-brain barrier suggests potential utility in treating primary and metastatic brain tumors. The compound was designed for improved potency and selectivity for its target kinases compared to earlier generation inhibitors.